Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $36.4 million.

  • Adma Biologics' Profit After Tax rose 144.53% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 20741.36%. This contributed to the annual value of $197.7 million for FY2024, which is 80000.0% up from last year.
  • As of Q3 2025, Adma Biologics' Profit After Tax stood at $36.4 million, which was up 144.53% from $34.2 million recorded in Q2 2025.
  • Adma Biologics' Profit After Tax's 5-year high stood at $111.9 million during Q4 2024, with a 5-year trough of -$25.0 million in Q1 2022.
  • In the last 5 years, Adma Biologics' Profit After Tax had a median value of -$6.8 million in 2023 and averaged $6.8 million.
  • As far as peak fluctuations go, Adma Biologics' Profit After Tax plummeted by 4425.59% in 2023, and later skyrocketed by 129996.1% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Profit After Tax stood at -$16.6 million in 2021, then rose by 26.54% to -$12.2 million in 2022, then tumbled by 44.26% to -$17.6 million in 2023, then surged by 734.15% to $111.9 million in 2024, then plummeted by 67.44% to $36.4 million in 2025.
  • Its Profit After Tax stands at $36.4 million for Q3 2025, versus $34.2 million for Q2 2025 and $26.9 million for Q1 2025.